OnCo
trialsTrialPositive

CheckMate 205

Established PD-1 blockade in relapsed Hodgkin lymphoma with ~70% response rates and seeded the frontline nivolumab-AVD idea.

ORR 69%, CR 16% across cohorts (median PFS ~15 months); accelerated approval May 2016. Cohort D (frontline N-AVD): CR 80%, 9-month mPFS 94%, the basis for S1826.

Setting
Relapsed/refractory classical Hodgkin lymphoma after autologous transplant: nivolumab (cohorts A-C); cohort D nivolumab-AVD frontline
Phase
Phase 2
Sponsor
BMS
Registry
NCT02181738
Headline result
ORR 69%.
Reported
2016
Enrolled
243

Outcomes

1top
In plain words
What these results mean for people, not percentages
243 people took part
Objective response rateprimaryresponse endpoint
  • 69 out of 100 people had their tumour shrink with Nivolumab.
  • There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
  • A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
  • These results apply to the people the trial enrolled: Relapsed/refractory classical Hodgkin lymphoma after autologous transplant: nivolumab (cohorts A-C); cohort D nivolumab-AVD frontline. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

243 participants enrolled.

Objective response rateprimary
Nivolumab69 of 100
n = 243
EndpointArmnValueHR (95% CI)pSource
Objective response rateprimaryNivolumab24369%———

Connected

3top

Pages like this

not linked directly; found by shared links

cancers

1
Hodgkin lymphoma

drugs

1
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)

pairings

1
PD-1 blockade + AVD chemotherapy